---
title: "Miglustat - Glucosylceramide Beta-Glucosidase Deficiency"
sidebar: mydoc_sidebar
permalink: db00419-mesh-d005776-1.html
toc: false 
---


Path ID: `DB00419_MESH_D005776_1`
{% include image.html url="images/db00419-mesh-d005776-1.png" file="db00419-mesh-d005776-1.png" alt="db00419-mesh-d005776-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C059896 | miglustat | Drug |
| UniProt:Q16739 | Ceramide glucosyltransferase | Protein |
| GO:0006679 | glucosylceramide biosynthetic process | BiologicalProcess |
| CHEBI:36500 | glucosylceramide | ChemicalSubstance |
| MESH:D005776 | Glucosylceramide beta-glucosidase deficiency | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Miglustat | DECREASES ACTIVITY OF | Ceramide Glucosyltransferase |
| Ceramide Glucosyltransferase | POSITIVELY REGULATES | Glucosylceramide Biosynthetic Process |
| Glucosylceramide Biosynthetic Process | INCREASES ABUNDANCE OF | Glucosylceramide |
| Glucosylceramide | POSITIVELY CORRELATED WITH | Glucosylceramide Beta-Glucosidase Deficiency |
|---------|-----------|---------|

Comment: Miglustat is an example of a substrate reduction therapy and it inhibits the synthesis of glucosylceramide (also known as glucocerebroside).

Reference: 
  - [https://go.drugbank.com/drugs/DB00419](https://go.drugbank.com/drugs/DB00419)
  - [https://en.wikipedia.org/wiki/Miglustat#Mechanism_of_action](https://en.wikipedia.org/wiki/Miglustat#Mechanism_of_action)
  - [https://en.wikipedia.org/wiki/Gaucher%27s_disease](https://en.wikipedia.org/wiki/Gaucher%27s_disease)
  - [https://en.wikipedia.org/wiki/Glucocerebrosidase#Clinical_significance](https://en.wikipedia.org/wiki/Glucocerebrosidase#Clinical_significance)
  - [https://en.wikipedia.org/wiki/Substrate_reduction_therapy](https://en.wikipedia.org/wiki/Substrate_reduction_therapy)
